Division of Urology, Department of Surgery, College of Medicine, University of Cincinnati, Ohio, USA.Department of Urology, Regional University of Lille, Lille, France; Bostwick Laboratories, Glen Allen, VA; Department of Pathology, Baylor College of Medicine, Houston, TX; Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy; Division of Urologic Surgery Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
What's known on the subject? and What does the study add? The recent shift of pathology stage migration towards an early forms suggested a great potential for an introduction of focal therapy into urology practice. Some body of the literature showed on increasing frequency of unilateral and unifocal lesions that can be efficiently treated with tumour ablative techniques. The internal panel of experts has done a comprehensive review of the largest mostly single institution studies and their own trails with the aim to evaluate a value of main pathological features of early stage of prostate cancer as a background to developing a concept of focal therapy. Analysis data including latest developments will help to better understand the purpose, meaning and patient selection of different kinds of focal targeted ablation of prostate cancer.
To better understand the biology and incidence of the cancer foci within the prostate through a comprehensive literature review and a review of our own data, to establish the current level of knowledge regarding the pathological foundation for active surveillance (AS) or focal therapy (FT).
A systematic review of the literature was performed, searching PubMed® from January 1994 to July 2009. Electronic searches were limited to the English language using the keywords 'prostate cancer', 'histopathology', 'radical prostatectomy', 'pathological stage' and 'focal therapy'. The authors' own data were also analysed and are presented.
Recent data have shown a significant pathological stage migration towards earlier disease comprising unilateral pT2a/b prostate cancer (PCa). The cancer volume of the clinically significant tumour (index lesion) has been proposed as a driving force of PCa progression and therefore should be identified and treated at an early stage. In general, most satellite lesions do not appear to be life-threatening. Other pathological features, such as Gleason score, extraprostatic extension and the spatial distribution of PCa within the prostate, remain important selective criteria for AS or FT.
The present study reviews the current knowledge of cancer focality, aggression and tumour volume. Further research is needed to better understand the biologic behaviour of each of the tumour foci within a cancerous prostate, and to employ this information to selected patients for no therapy (AS), parenchyma-preserving approaches (FT) or whole gland radical therapy.
Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ. Are you the author?
Reference: BJU Int. 2011 Apr 13. Epub ahead of print.